These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1143 related articles for article (PubMed ID: 29298886)

  • 21. The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication.
    Walker-Sperling VE; Pohlmeyer CW; Tarwater PM; Blankson JN
    EBioMedicine; 2016 Jun; 8():217-229. PubMed ID: 27428432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in structure-activity relationships of HDAC inhibitors as HIV latency-reversing agents.
    Khatun S; Amin SA; Choudhury D; Chowdhury B; Jha T; Gayen S
    Expert Opin Drug Discov; 2024 Mar; 19(3):353-368. PubMed ID: 38258439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1.
    López-Huertas MR; Jiménez-Tormo L; Madrid-Elena N; Gutiérrez C; Rodríguez-Mora S; Coiras M; Alcamí J; Moreno S
    Sci Rep; 2017 May; 7(1):2385. PubMed ID: 28539614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histone deacetylase inhibitors induce complex host responses that contribute to differential potencies of these compounds in HIV reactivation.
    Beliakova-Bethell N; Mukim A; White CH; Deshmukh S; Abewe H; Richman DD; Spina CA
    J Biol Chem; 2019 Apr; 294(14):5576-5589. PubMed ID: 30745362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reactivation of latent HIV by histone deacetylase inhibitors.
    Shirakawa K; Chavez L; Hakre S; Calvanese V; Verdin E
    Trends Microbiol; 2013 Jun; 21(6):277-85. PubMed ID: 23517573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal.
    Stoszko M; De Crignis E; Rokx C; Khalid MM; Lungu C; Palstra RJ; Kan TW; Boucher C; Verbon A; Dykhuizen EC; Mahmoudi T
    EBioMedicine; 2016 Jan; 3():108-121. PubMed ID: 26870822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
    Acchioni C; Remoli AL; Marsili G; Acchioni M; Nardolillo I; Orsatti R; Farcomeni S; Palermo E; Perrotti E; Barreca ML; Sabatini S; Sandini S; Parolin C; Lin R; Borsetti A; Hiscott J; Sgarbanti M
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31243131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1.
    Choi BS; Lee HS; Oh YT; Hyun YL; Ro S; Kim SS; Hong KJ
    AIDS; 2010 Feb; 24(4):609-11. PubMed ID: 20154582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A histone deacetylase network regulates epigenetic reprogramming and viral silencing in HIV-infected cells.
    Peterson JJ; Lewis CA; Burgos SD; Manickam A; Xu Y; Rowley AA; Clutton G; Richardson B; Zou F; Simon JM; Margolis DM; Goonetilleke N; Browne EP
    Cell Chem Biol; 2023 Dec; 30(12):1617-1633.e9. PubMed ID: 38134881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation.
    Williams SA; Chen LF; Kwon H; Ruiz-Jarabo CM; Verdin E; Greene WC
    EMBO J; 2006 Jan; 25(1):139-49. PubMed ID: 16319923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective BCL-X
    Ren Y; Huang SH; Macedo AB; Ward AR; Alberto WDC; Klevorn T; Leyre L; Copertino DC; Mota TM; Chan D; Truong R; Rohwetter T; Zumbo P; Dündar F; Betel D; Kovacs C; Benko E; Bosque A; Jones RB
    J Virol; 2021 Jul; 95(15):e0242520. PubMed ID: 33980597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.
    Bullen CK; Laird GM; Durand CM; Siliciano JD; Siliciano RF
    Nat Med; 2014 Apr; 20(4):425-9. PubMed ID: 24658076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of the effect of HDAC inhibitors on the formation of the HIV reservoir.
    Ling L; Kim M; Soper A; Kovarova M; Spagnuolo RA; Begum N; Kirchherr J; Archin N; Battaglia D; Cleveland D; Wahl A; Margolis DM; Browne EP; Garcia JV
    mBio; 2024 Sep; 15(9):e0163224. PubMed ID: 39136440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective HDAC inhibition for the disruption of latent HIV-1 infection.
    Barton KM; Archin NM; Keedy KS; Espeseth AS; Zhang YL; Gale J; Wagner FF; Holson EB; Margolis DM
    PLoS One; 2014; 9(8):e102684. PubMed ID: 25136952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents.
    Marsden MD; Wu X; Navab SM; Loy BA; Schrier AJ; DeChristopher BA; Shimizu AJ; Hardman CT; Ho S; Ramirez CM; Wender PA; Zack JA
    Virology; 2018 Jul; 520():83-93. PubMed ID: 29800728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
    Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histone deacetylase inhibition reduces deleterious cytokine release induced by ingenol stimulation.
    Larragoite ET; Nell RA; Martins LJ; Barrows LR; Planelles V; Spivak AM
    Biochem Pharmacol; 2022 Jan; 195():114844. PubMed ID: 34801521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A CRISPR/Cas9 screen identifies the histone demethylase MINA53 as a novel HIV-1 latency-promoting gene (LPG).
    Huang H; Kong W; Jean M; Fiches G; Zhou D; Hayashi T; Que J; Santoso N; Zhu J
    Nucleic Acids Res; 2019 Aug; 47(14):7333-7347. PubMed ID: 31165872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages.
    Hany L; Turmel MO; Barat C; Ouellet M; Tremblay MJ
    J Virol; 2022 Feb; 96(4):e0195321. PubMed ID: 34878918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
    Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.